Hao Fang，Ph.D.

Professor of Medicinal Chemistry

Vice Director of Scientific Research and International 

Affairs Shandong University Cheeloo College of Medicine

Ji’nan, 250012, P. R. China

Tel: 86-531-88382019

Fax: 86-531-88382548

Email: haofangcn@sdu.edu.cn

Web site: /english/info/1036/1380.htm

Education

Ph.D.  July 2001, Department of Medicinal Chemistry, School of Pharmacy,
China Pharmaceutical University

B.S.  July 1996, School of Pharmacy, China Pharmaceutical University

Professional Experience

Jan 2008-present    Professor and Associate Dean, School of Pharmacy, Shandong University

Dec 2004-2007    Associate Professor, School of pharmacy, Department of Medicinal Chemistry,Shandong University

Jul 2003-Dec 2004   Post-Doctoral Research Associate with Professor Binghe Wang, Department of Chemistry, Georgia State University.

Sep 2002-Jul 2003   Post-Doctoral Research Associate with Professor Binghe Wang, Department of Chemistry, North Carolina State University.

Sep 2001-Aug 2002   Post-Doctoral Research Associate with Professor Ronald. W. Woodard, College of Pharmacy, University of Michigan.

Research Interest

1) Medicinal Chemistry: Structure-based drug design on the targets for cancer therapy, including histone deacetylase (HDAC), Bcl-2 and Cyclin-dependent kinase (CDK) etc.
2) Bioorganic chemistry/molecular recognition: Development of fluorescent sensors for the recognition of tumor-cell surface oligosaccharides;

Honors, Awards and Recognitions

1)The 8th “My Favorite Advisor” in Shandong University,2016    

2)The 9th International symposium for Chinese Medicinal Chemists     Outstanding Oral Presentation, ACS Publications, 2014

3) New Century Excellent Talents in University, Ministry of Education of China , 2012

4) 14th CPA-Servier Young Investigator Awards in Medicinal Chemistry, Chinese Pharmaceutical Association, 2011

5) International Medical Communication Young Award, Japan-China Joint Medical Workshop on Drug Discovery and Therapeutics, 2008, Tokyo.

6) Member of Editorial Board, Letters in Drug Design., since 2013

7) Member of Editorial Board, Acta Pharmaceutica Sinica., since 2013

8) Member of Editorial Board, China Pharmaceutical Industry. since 2012

Research Founding

1) Studies on design, synthesis and bioactivity of novel Mcl-2 inhibitors, PI, National Natural Science Foundation of China (NSFC 21672127), 2017-2020.

2) Studies on novel dual inhibitors of HDAC and Bcl-2 inhibitors, PI, National Natural Science Foundation of China (NSFC 81373281), 2014-2017.

3) Medicinal Chemistry, PI, Shandong Natural Science Fund for Distinguished Young Scholars (No. JQ201319), 2014-2016.

4) Design, synthesis and biological studies of new Bcl-2 inhibitors based on WL-276 structure, PI, National Natural Science Foundation of China (NSFC 21172133), 2012-2015.

5) Design and synthesis of thiadiazole derivatives as histone deacetylase inhibitors, PI, Shandong Provincial Natural Science Foundation, China (ZR2010HM028), 2011-2013.

6) Medicinal Chemistry，Co-PI with Chengguo Xing of University of Minnesota, NSFC of Joint Research Fund for Overseas Chinese Young Scholars( NSFC 30728031), 2008-2010.

7) Design and synthesis of water-soluble fluorescent sensors for tumor cell surface oligosaccharide, PI, National Natural Science Foundation of China (NSFC 20602023), 2007-2009.

Publication

1) Hou X, Li R, Li K, Yu X, Sun J, Fang H*. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014, 57, 9309-9322.

2) Hou X, Du J, Liu R, Zhou Y, Li M, Xu W, Fang H*. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8. J. Chem. Inf. Model. 2015, 55, 861-871.

3) Hou X, Li K, Yu X, Sun J, Fang H*. Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures. J. Chem. Inf. Model. 2015, 55, 1973-1983.

4) Liu T, Wan Y, Liu R, Ma L, Li M, Fang H*. Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors. Bioorg. Med. Chem. 2017, 25, 1939-1948.

5) Wan Y, Liu T, Li X, Chen C, Fang H*. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains. Bioorg. Med. Chem. 2017, 25, 138-152.

6) Liang T, Li J, Fang J, Liu T, Fang H*. Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives. Chin. J. Org. Chem. 2017 ASAP.

7) Liu R, Wang J, Tang W, Fang H*. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Bioorg. Med. Chem. 2016, 24, 1446-1454.

8) Liu T, Wan Y, Fang H*. Synthesis and Antiproliferative Activity of Novel 1,3,4-Thiadiazole Derivatives. Chin. J. Org. Chem. 2016, 36, 417-424.

9) Pan X, Wang L, Dun Y, Fang H*. Synthesis and Antiproliferative Activity Studies on 2-Substitued Aniline Quinazoline Derivatives. Chin. J. Org. Chem. 2016, 36, 1044-1050.

10) Chen Y, Su L, Yang X, Pan W, Fang H*. Enantioselective synthesis of 3,5-disubstituted thiohydantoins and hydantoins. Tetrahedron. 2015, 71, 9234-9239.

11) Fu H, Han L, Hou X, Dun Y, Wang L, Gong X, Fang H*. Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors. Bioorg. Med. Chem. 2015, 23, 5774-5781.

12) Wan Y, Wang J, Sun F, Chen M, Hou X, Fang H*. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors. Bioorg. Med. Chem. 2015,   23, 7685-7693.

13) Wan Y, Wu S, Xiao G, Liu T, Hou X, Chen C, Guan P, Yang X, Fang H*. Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors. Bioorg. Med. Chem. 2015, 23, 1994-2003.

14) Wang G, Wang Y, Wang L, Han L, Hou X, Fu H, Fang H*. Design, synthesis and preliminary bioactivity studies of imidazolidine-2,4-dione derivatives as Bcl-2 inhibitors. Bioorg. Med. Chem. 2015, 23, 7359-7365.

15) Wang L, Hou X, Fu H, Pan X, Xu W, Tang W, Fang H*. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. 2015, 23, 4364-4374.

16) Fu H,  Hou X, Wang L, Dun Y, Yang X,  Fang H*. Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 5265-5269.

17) Wan Y, Liu T, Hou X, Dun Y, Guan P, Fang H*. Antagonists of IAP proteins: novel anti-tumor agents. Curr Med Chem. 2014, 21, 3877-3892.

18) Yang X, Su L, Hou X, Ding S, Xu W, Wang B, Fang H*. High-performance liquid chromatographic enantioseparation of 3,5-disubstituted hydantoins analogs and temperature-induced reversals of elution orders on a polysaccharide-based chiral stationary phase. J. Chromatogr A .2014, 1355, 291-295.

19) Guan P, Wang L, Hou X, Wan Y,  Xu W, Tang W, Fang H*. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. Bioorg. Med. Chem. 2014, 22, 5766-5775.

20) Han L, Wang L, Hou X, Fu H, Song W, Tang W, Fang H*. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorg. Med. Chem. 2014, 22, 1529-1538.

21) Wang J, Sun F, Han L, Hou X, Pan X, Liu R, Tang W, Fang H*. Design, synthesis, and preliminary bioactivity studies of substituted purine hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors. Med. Chem. Commun. 2014, 5, 1887-1891.